Clicky

MediWound Ltd.(MDWD) News

Date Title
May 13 Investors in MediWound (NASDAQ:MDWD) have seen decent returns of 65% over the past year
Apr 25 MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
Apr 17 Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
Mar 25 Wall Street Analysts See a 76.89% Upside in MediWound (MDWD): Can the Stock Really Move This High?
Mar 25 What Makes MediWound (MDWD) a Good Fit for 'Trend Investing'
Mar 24 MediWound Ltd. (NASDAQ:MDWD) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 21 MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
Mar 21 MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
Mar 14 MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
Mar 7 Retail investors who hold 38% of MediWound Ltd. (NASDAQ:MDWD) gained 15%, institutions profited as well
Mar 6 MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?
Feb 12 MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
Jan 15 MediWound (MDWD)'s Technical Outlook is Bright After Key Golden Cross
Jan 9 Wall Street Analysts Think MediWound (MDWD) Could Surge 134.77%: Read This Before Placing a Bet
Jan 9 MediWound (MDWD): Strong Industry, Solid Earnings Estimate Revisions
Jan 9 MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
Dec 28 MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
Dec 21 MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
Dec 5 MediWound (NASDAQ:MDWD) investors are sitting on a loss of 75% if they invested five years ago
Nov 27 Does MediWound (MDWD) Have the Potential to Rally 223.05% as Wall Street Analysts Expect?